Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors - Ecaterina E. Dumbrava; Geoffrey I. Shapiro; Aparna R. Parikh; Melissa L. Johnson; Anthony W. Tolcher; John A. Thompson; Anthony B. El-Khoueiry; Andrae L. Vandross; Shivaani Kummar; Dale R. Shepard; Kim LeDuke; Lisa Sheehan; et al. (New England Journal of Medicine, 2026)